Panbela Announces Poster Presentation at American Association for Cancer Research:
Panbela Therapeutics, Inc. (PBLA)
Company Research
Source: GlobeNewswire
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research (AACR), which took place April 10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine. “Ivospemin, reduces the viability of human ovarian adenocarcinoma cell lines regardless of their platinum sensitivity and we found that the combination treatment with doxorubicin increases median survival, delays tumor onset, and decreases overall tumor burden compared to either clinical or subclinical doxorubicin dosing schemes." said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. “The continued wo
Show less
Read more
Impact Snapshot
Event Time:
PBLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBLA alerts
High impacting Panbela Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PBLA
News
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024GlobeNewswire
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekGlobeNewswire
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 [Yahoo! Finance]Yahoo! Finance
- Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025GlobeNewswire
- Panbela Announces Poster Presentation at American Association for Cancer Research: [Yahoo! Finance]Yahoo! Finance
PBLA
Earnings
- 3/26/24 - Miss
PBLA
Sec Filings
- 4/26/24 - Form PRER14A
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form 8-K
- PBLA's page on the SEC website